Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 9:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 618 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: placebo oral solution Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants

NCT06345755
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions
VX-407, Placebo, Midazolam
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
159 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2025 · Synced Sep 5, 2026, 9:55 PM EDT
Terminated Phase 2 Interventional Results available

Treatment of Septic Shock by Inhibiting Autodigestion and Preserving Gut Integrity With Enteric LB1148

NCT02317549
View directory record Official record
Conditions
Septic Shock
Interventions
LB1148, Placebo
Drug
Lead sponsor
Leading BioSciences, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
26
States / cities
Mobile, Alabama • Fresno, California • Long Beach, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 31, 2020 · Synced Sep 5, 2026, 9:55 PM EDT
Completed Phase 2 Interventional Results available

Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection

NCT01257204
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
Placebo, Daclatasvir, Pegylated interferon alfa-2a, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Tulsa, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2015 · Synced Sep 5, 2026, 9:55 PM EDT
Completed Phase 3 Interventional Results available

Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

NCT03615326
View directory record Official record
Conditions
Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma
Interventions
Pembrolizumab, Placebo, Cisplatin, 5-FU, Oxaliplatin, Capecitabine, S-1, Trastuzumab
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
738 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
23
States / cities
Los Angeles, California • Monterey, California • Orange, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 5, 2026, 9:55 PM EDT
Completed Phase 2 Interventional Results available

BCAA Supplementation for Concussion

NCT01860404
View directory record Official record
Conditions
Brain Concussion
Interventions
Branched Chain Amino Acids, Placebo solution
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
11 Years to 34 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 13, 2024 · Synced Sep 5, 2026, 9:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Randomized, Double Blind Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986166 in Healthy Subjects

NCT02790125
View directory record Official record
Conditions
Healthy
Interventions
BMS-986166, Placebo matching BMS-986166
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 23, 2017 · Synced Sep 5, 2026, 9:55 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to Healthy Subjects

NCT02696291
View directory record Official record
Conditions
Viral Infection
Interventions
UV-4B 30 mg oral solution, UV-4B 75 mg oral solution, UV-4B 150 mg oral solution, UV-4B X mg (dose to be determined) oral solution, UV-4B Y mg (dose to be determined) oral solution, Placebo
Drug
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 45 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Dallas, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 17, 2024 · Synced Sep 5, 2026, 9:55 PM EDT
Completed Not applicable Interventional Results available

Pain and Anxiety Management With Oral Narcotic for Pediatric Suture Repair

NCT01053637
View directory record Official record
Conditions
Children, Lacerations, Procedures, Child, Pain
Interventions
hydrocodone/acetaminophen, Sugar water
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
2 Years to 17 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Sep 5, 2026, 9:55 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Phase I Study to Evaluate the Safety and Pharmacokinetics of Oral Doses of Anvylic-3288 in Healthy Subjects

NCT01851603
View directory record Official record
Conditions
Schizophrenia
Interventions
AVL-3288, Placebo
Device · Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 29, 2016 · Synced Sep 5, 2026, 9:55 PM EDT
Completed Phase 1 Interventional

Single Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes

NCT01105429
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
BMS-820132, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
3
States / cities
Chula Vista, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 8, 2011 · Synced Sep 5, 2026, 9:55 PM EDT
Completed Phase 3 Interventional Results available

OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis

NCT02054156
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
azithromycin, placebo, Tobramycin solution for inhalation
Drug
Lead sponsor
Bonnie Ramsey
Other
Eligibility
6 Months to 18 Years
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
45
States / cities
Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Sep 5, 2026, 9:55 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Immediate Post-Operative Anesthesia With Either Lidocaine or Bupivacaine

NCT06293807
View directory record Official record
Conditions
Periodontal Diseases
Interventions
Xylocaine 2 % with 1:100,000 epinephrine, Bupivicaine 0.5% with 1:200,000 epinephrine, Placebo
Drug · Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 7, 2024 · Synced Sep 5, 2026, 9:55 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation

NCT02709109
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-371 + HS, Hypertonic saline, Placebo, Orkambi, VX-371
Drug
Lead sponsor
Parion Sciences
Industry
Eligibility
12 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
30
States / cities
Little Rock, Arkansas • Oakland, California • Gainesville, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Sep 5, 2026, 9:55 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis

NCT00430677
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Corticosteroids (prednisone or prednisolone), Abatacept, Mycophenolate mofetil (MMF)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
423 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
14
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2015 · Synced Sep 5, 2026, 9:55 PM EDT
Terminated Phase 4 Interventional Results available

Suprainguinal Fascia Iliaca (SIFI) Block Improves Analgesia Following Total Hip Arthroplasty

NCT02933671
View directory record Official record
Conditions
Hip Osteoarthritis, Primary Total Hip Arthroplasty, Pain
Interventions
Suprainguinal fascia iliaca (SIFI) block, Sham block, Ropivacaine, Saline
Procedure · Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Sep 5, 2026, 9:55 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC)

NCT03905330
View directory record Official record
Conditions
Progressive Familial Intrahepatic Cholestasis (PFIC)
Interventions
Maralixibat, Placebo
Drug · Other
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
1 Year to 17 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
11
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Orlando, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2023 · Synced Sep 5, 2026, 9:55 PM EDT
Completed Phase 3 Interventional Results available

Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease

NCT04380142
View directory record Official record
Conditions
Parkinson's Disease (PD)
Interventions
ABBV-951, Placebo for Levodopa/Carbidopa (LD/CD), Levodopa/Carbidopa (LD/CD), Placebo for ABBV-951
Drug
Lead sponsor
AbbVie
Industry
Eligibility
30 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
70
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2022 · Synced Sep 5, 2026, 9:55 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

In-Vivo Assessment of Silver Biomaterial Nano-Toxicity 32 Ppm

NCT01405794
View directory record Official record
Conditions
Healthy
Interventions
32ppm Silver Particle, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 3, 2016 · Synced Sep 5, 2026, 9:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety and Immunogenicity of KBP-V001 Quadrivalent Influenza Vaccine in Healthy Adults

NCT04439695
View directory record Official record
Conditions
Influenza
Interventions
Low dose, Intermediate dose, High dose, Placebo
Biological
Lead sponsor
KBio Inc
Industry
Eligibility
18 Years to 49 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 15, 2021 · Synced Sep 5, 2026, 9:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Two-part Multiple Dose Study to Assess the Safety and Effects of AZD3293 in Healthy Elderly and Alzheimer's Patients

NCT01795339
View directory record Official record
Conditions
Healthy Elderly Volunteers, Mild-to-moderate Alzheimer's Disease Patients
Interventions
AZD3293, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
55 Years to 80 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Apr 2, 2014 · Synced Sep 5, 2026, 9:55 PM EDT
Active, not recruiting Phase 2 Interventional

Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2)

NCT07220629
View directory record Official record
Conditions
Obesity
Interventions
NT-0796, Placebo
Drug
Lead sponsor
NodThera Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
9
States / cities
Mesa, Arizona • Hialeah, Florida • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Sep 5, 2026, 9:55 PM EDT
Completed Phase 3 Interventional Results available

Novel Use of (Oral) Ketotifen for the Treatment of Fibromyalgia: A Pilot Study

NCT01553318
View directory record Official record
Conditions
Fibromyalgia
Interventions
Ketotifen, Placebo (Sugar Pill)
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 16, 2016 · Synced Sep 5, 2026, 9:55 PM EDT
Recruiting Phase 2 Interventional

Investigating a Marijuana-based Compound as a Treatment for Anxiety in Autistic Adults

NCT06526208
View directory record Official record
Conditions
Autism Spectrum Disorder, Anxiety
Interventions
MB-IMP, Placebo
Drug · Other
Lead sponsor
Southwest Autism Research & Resource Center
Other
Eligibility
18 Years to 45 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Sep 5, 2026, 9:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy of Different Oral Rehydration Solutions on the Hydration Status of Healthy Males

NCT05428774
View directory record Official record
Conditions
Fluid Retention, Beverage Hydration Index, Hydration Status
Interventions
Test product 1, Test product 2, Placebo
Other
Lead sponsor
Liquid I.V.
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 24, 2023 · Synced Sep 5, 2026, 9:55 PM EDT